Clinical Trial

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-01-26; most recent amendment 2025-03-28.
Status change: Not Yet Recruiting → Active, Not Recruiting 2024-03-29
Trial Details
NCT Number NCT05701774
Lead Sponsor Soleno Therapeutics, Inc.
Conditions Prader-Willi Syndrome
Enrollment 83 participants
Start Date 2023-01-31
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-04-02